PBAC's latest decision on Latanoprost with timolol maleate: Recommended with restriction (2005). Considered for Reduction of elevated intraocular pressure in patients with open angle glaucoma who are not adequately controlled with timolol maleate 5mg (base) per mL (0.5%) (twice daily) eye drops or who are insufficiently responsive to latanoprost or other intraocular pressure lowering medication; Reduction of elevated intra-ocular pressure in patients with ocular hypertension, who are not adequately controlled with timolot maleate 5mg (base) per mL (0.5%) eye drops or who are insufficiently responsive to latanoprost or other intraocular pressure lowering medication.
PBAC outcome
Recommended with restriction
Restricted Benefit
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2005
Submissions
2
2005 → 2005
Eligible population
patients with open angle glaucoma or ocular hypertension who are not adequately controlled with timolol maleate, latanoprost, or other intraocular pressure lowering medications
Therapy area
Ophthalmology
Evidence base
RCT
Primary endpoint
IOP reduction
Key trials
Trial 004, Konstas trial
Comparator
unfixed combination of latanoprost and timolol (two mono-therapies used in combination)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis presented; no ICER calculated
Submission history
Jul 2005: Deferred · Restricted
Nov 2005: Recommended with restriction · Restricted Benefit